Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Synfini, Inc. logo — The Agile Drug Discovery Company

Synfini, Inc.

The Agile Drug Discovery Company

Founded 2023 United States Menlo Park, United States 14 employees Total: $10.40M AI, Pharmaceutical

General Information

Company Name Synfini, Inc.
Founded Year 2023
Location United States Menlo Park, United States
Employees 14
Industries AI, Pharmaceutical
Business Model B2B, SaaS, Platform
Revenue Model Subscription, Usage Based, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Synfini, Inc.. To contact Synfini, Inc., visit synfini.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Synfini, Inc. compare?

A PDF of Synfini, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Synfini, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Synfini, Inc.

Synfini, Inc., branded as The Agile Drug Discovery Company, is revolutionizing the pharmaceutical industry through its cutting-edge, automated molecular discovery platform. Leveraging advancements in integrated neuro-symbolic AI, robotic automation, and a robust chemical data repository, this Menlo Park, California-based startup is at the forefront of agile chemistry.

Founded in 2023, Synfini utilizes patented technologies from SRI International to offer accelerated molecular discovery services, catering primarily to pharmaceutical companies globally. This startup resides in the overlapping industries of AI and Pharmaceutical.

The company recently closed an $8.90M Early VC investment round on 01 July 2025, backed by prominent firms including Foothill Ventures, Gaingels, Trust Ventures, and others. Such substantial backing highlights investor confidence in Synfini’s transformational potential in drug discovery.

Business keywords: agile chemistry, molecular discovery, neuro-symbolic AI, robotic automation, drug discovery, chemical synthesis technologies, automated chemical synthesis, SRI International partnership, world-class chemistry data, pharmaceutical industry, accelerated drug discovery, automation in drug discovery, drug hunters

Services & Products

Integrated AI molecular design
Automated synthesis and testing
Generative design
Discovery workflows and planning
Hosted AI models

Target Customers

Pharmaceutical companies Biotech researchers Drug hunters Discovery teams Pharma companies under regulatory pressure

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC $8.90M 9
Foothill Ventures Gaingels Trust Ventures
Foothill Ventures, Gaingels +7
01 Jul 2025
Seed $1.50M 1
WERU Investment
WERU Investment
01 Sep 2023

Latest News

View All
Synfini gets $8.9M to accelerate drug discovery with AI — Siliconangle.com
Synfini gets $8.9M to accelerate drug discovery with AI
Siliconangle.com Jul 07, 2025

Synfini, Inc. Alternatives & Competitors

View All Alternatives
Synfini, Inc. vs
iktos
iktos France

Artificial intelligence for new drug design

Series A
62 employees
AI, Biotechnology
Synfini, Inc. vs
Standigm
Standigm Korea South

The workflow AI drug discovery company

Growth
23 employees
AI, Biotechnology
Synfini, Inc. vs
Menten AI
Menten AI United States

Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Ge...

Seed
19 employees
AI, Biotechnology
View all alternatives

FAQ About Synfini, Inc.

The Agile Drug Discovery Company
Synfini, Inc. was founded in 2023.
Synfini, Inc. is headquartered in Menlo Park, United States.
Synfini, Inc. operates in AI and Pharmaceutical. Its work centres on agile chemistry, molecular discovery, neuro-symbolic AI and robotic automation. Its customers include Pharmaceutical companies, Biotech researchers and Drug hunters.
Synfini, Inc. has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Licensing.
Synfini, Inc. has approximately 14 employees.
Synfini, Inc. has completed 2 funding rounds, raising a total of $10.40M.
Synfini, Inc. offers: Integrated AI molecular design, Automated synthesis and testing, Generative design, Discovery workflows and planning, Hosted AI models.
Top alternatives and competitors to Synfini, Inc. include iktos, Standigm, Menten AI. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Synfini, Inc. and iktos are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Synfini, Inc., https://bouncewatch.com/company/synfini-inc, updated 4 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout